Modulation of tudor-sn expression

Abstract

Compounds, compositions and methods are provided for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided.

1 . An oligomeric compound 13 to 50 nucleobases in length hybridizable under physiological conditions to a region within nucleotides 325 to 1660 of SEQ ID NO:4, wherein the compound comprises at least one modified nucleobase, sugar, or internucleoside linkage. 
     
     
         2 . The compound of  claim 1  wherein the compound is hybridizable under physiological conditions to a region within nucleotides 325 to 898 of SEQ ID NO:4. 
     
     
         3 . The compound of  claim 2  wherein the compound is hybridizable under physiological conditions to a region within nucleotides 661 to 680 of SEQ ID NO:4. 
     
     
         4 . The compound of  claim 1  wherein the compound is hybridizable under physiological conditions to a region within nucleotides 1014 to 1660 of SEQ ID NO:4. 
     
     
         5 . The compound of  claim 4  wherein the compound is hybridizable under physiological conditions to a region within nucleotides 1515 to 1534 of SEQ ID NO:4. 
     
     
         6 . The compound of  claim 1  which is 15 to 30 nucleobases in length. 
     
     
         7 . The compound of  claim 1  which is a DNA oligonucleotide or RNA oligonucleotide. 
     
     
         8 . The compound of  claim 1  which is a chimeric oligonucleotide. 
     
     
         9 . The compound of  claim 1  wherein the modified sugar is a 2′-O-methoxyethyl sugar moiety, wherein the modified oligonucleoside linkage is a phosphorothioate internucleoside linkage, and wherein the modified nucleobase is a 5-methylcytosine. 
     
     
         10 . The compound of  claim 1  which is double-stranded. 
     
     
         11 . An oligomeric compound-RNA duplex wherein the oligomeric compound of the duplex is a compound of  claim 1 , and wherein the RNA of the duplex is an RNA that encodes at least the portion of SEQ ID NO:4 to which the oligomeric compound hybridizes. 
     
     
         12 . A method of inhibiting the expression of Tudor-SN in a cell, tissue, or animal comprising contacting the cell, tissue, or animal with a compound of  claim 1 . 
     
     
         13 . A composition comprising a compound of  claim 1 . 
     
     
         14 . The composition of  claim 13  further comprising a pharmaceutically acceptable salt or carrier. 
     
     
         15 . A kit or assay device comprising a compound of  claim 1 . 
     
     
         16 . A method of treating an animal having a disease or condition associated with Tudor-SN comprising administering to the animal a therapeutically or prophylactically effective amount of a compound of  claim 1  so that expression of Tudor-SN is inhibited. 
     
     
         17 . The method of  claim 16  wherein the disease or condition is inflammation. 
     
     
         18 . A method of inducing apoptosis in a breast carcinoma cell comprising contacting the breast carcinoma cell with a compound of  claim 1  so that expression of Tudor-SN is inhibited. 
     
     
         19 . The method of  claim 18  wherein the compound is 20 nucleobases in length.